ENTYVIO
Takeda Pharmaceuticals is dedicated to providing innovative treatments for adults with moderate to severe ulcerative colitis (UC) and Crohn's disease. Their mission is to offer gut-focused therapies that work right where patients need relief, with a focus on safety, efficacy, and patient support. They aim to improve the quality of life for individuals living with these chronic conditions through their flagship product, ENTYVIO (vedolizumab), which is the #1 prescribed biologic for Crohn's and ulcerative colitis combined.
Industries
Nr. of Employees
small (1-50)
Products
Biologic therapy (vedolizumab) — IV formulation and prefilled subcutaneous autoinjector
A monoclonal antibody biologic for adults with moderate to severe ulcerative colitis or Crohn's disease, delivered as an intravenous infusion for induction and optionally as a prefilled single-dose subcutaneous autoinjector for maintenance after initial IV doses.
Biologic therapy (vedolizumab) — IV formulation and prefilled subcutaneous autoinjector
A monoclonal antibody biologic for adults with moderate to severe ulcerative colitis or Crohn's disease, delivered as an intravenous infusion for induction and optionally as a prefilled single-dose subcutaneous autoinjector for maintenance after initial IV doses.
Services
Enrollment-based program providing co-pay assistance (eligibility-based), nurse educator guidance, injection training kits, treatment reminders, and enrollment/start services to help patients initiate and maintain therapy.
Coordination of specialty pharmacy shipment for subcutaneous autoinjector delivery and tools to locate infusion centers for IV administration, including benefits verification and prior authorization assistance.
Enrollment-based program providing co-pay assistance (eligibility-based), nurse educator guidance, injection training kits, treatment reminders, and enrollment/start services to help patients initiate and maintain therapy.
Coordination of specialty pharmacy shipment for subcutaneous autoinjector delivery and tools to locate infusion centers for IV administration, including benefits verification and prior authorization assistance.
Expertise Areas
- Inflammatory bowel disease therapeutics
- Biologic drug dosing and administration (IV and subcutaneous)
- Clinical trial management and long-term extension studies
- Safety monitoring and pharmacovigilance for biologics
Key Technologies
- Monoclonal antibody biologic targeting α4β7 integrin
- Intravenous infusion delivery
- Prefilled subcutaneous autoinjector (single-dose pen)
- Clinical outcome measurement (CDAI and remission endpoints)
News & Updates
Quarterly analysis of claims data from June 2022–September 2024.
Quarterly analysis of claims data from June 2022–September 2024.
Quarterly analysis of claims data from June 2022–September 2024.
Quarterly analysis of claims data from June 2022–September 2024.